NZ733670A - Insulin glargine/lixisenatide fixed ratio formulation - Google Patents
Insulin glargine/lixisenatide fixed ratio formulationInfo
- Publication number
- NZ733670A NZ733670A NZ733670A NZ73367015A NZ733670A NZ 733670 A NZ733670 A NZ 733670A NZ 733670 A NZ733670 A NZ 733670A NZ 73367015 A NZ73367015 A NZ 73367015A NZ 733670 A NZ733670 A NZ 733670A
- Authority
- NZ
- New Zealand
- Prior art keywords
- fixed ratio
- insulin glargine
- ratio formulation
- lixisenatide fixed
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14197685 | 2014-12-12 | ||
| EP15193940 | 2015-11-10 | ||
| PCT/EP2015/079285 WO2016092026A1 (en) | 2014-12-12 | 2015-12-10 | Insulin glargine/lixisenatide fixed ratio formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ733670A true NZ733670A (en) | 2021-12-24 |
Family
ID=54848560
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ733670A NZ733670A (en) | 2014-12-12 | 2015-12-10 | Insulin glargine/lixisenatide fixed ratio formulation |
Country Status (32)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3228320T3 (pl) | 2008-10-17 | 2020-06-01 | Sanofi-Aventis Deutschland Gmbh | Kombinacja insuliny i agonisty GLP-1 |
| SI2498801T1 (en) | 2009-11-13 | 2018-06-29 | Sanofi-Aventis Deutschland Gmbh | A pharmaceutical composition containing desPro36Exendin-4 (1-39) -Lys6-NH2 and methionine |
| PE20171622A1 (es) | 2014-12-12 | 2017-11-02 | Sanofi Aventis Deutschland | Formulacion de relacion fija de insulina glargina/lixisenatida |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| US10894142B2 (en) | 2016-03-24 | 2021-01-19 | Trudell Medical International | Respiratory care system with electronic indicator |
| WO2018055539A1 (en) * | 2016-09-22 | 2018-03-29 | Wockhardt Limited | Pharmaceutical composition containing buffered insulin glargine and glp-1 analogue |
| AU2018308692A1 (en) * | 2017-07-27 | 2020-03-05 | Adocia | Compositions in the form of an injectable aqueous solution comprising at least human insulin A21G and a prandial action glucagon suppressor |
| US20210093698A1 (en) * | 2019-09-13 | 2021-04-01 | Sanofi | Treatment of type 2 diabetes mellitus |
| US11160925B1 (en) * | 2021-01-29 | 2021-11-02 | Insulet Corporation | Automatic drug delivery system for delivery of a GLP-1 therapeutic |
| US20220397560A1 (en) * | 2021-06-10 | 2022-12-15 | Thermo Finnigan Llc | Auto outlier injection identification |
| CN116083583A (zh) * | 2023-01-16 | 2023-05-09 | 中国人民解放军海军军医大学第一附属医院 | miRNA-483-5p在制备胰腺癌肝转移诊断试剂盒中的应用 |
Family Cites Families (403)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US975286A (en) * | 1910-03-05 | 1910-11-08 | Charles H A F L Ross | Trigger mechanism. |
| GB835638A (en) | 1956-12-01 | 1960-05-25 | Novo Terapeutisk Labor As | Insulin crystal suspensions having a protracted effect |
| GB840870A (en) | 1957-08-03 | 1960-07-13 | Novo Terapeutisk Labor As | Improvements in or relating to insulin preparations |
| US3868358A (en) | 1971-04-30 | 1975-02-25 | Lilly Co Eli | Protamine-insulin product |
| US3758683A (en) | 1971-04-30 | 1973-09-11 | R Jackson | Insulin product |
| US4153689A (en) | 1975-06-13 | 1979-05-08 | Takeda Chemical Industries, Ltd. | Stable insulin preparation for nasal administration |
| GB1554157A (en) | 1975-06-13 | 1979-10-17 | Takeda Chemical Industries Ltd | Stable insulin preparation for intra nasal administration |
| GB1527605A (en) | 1975-08-20 | 1978-10-04 | Takeda Chemical Industries Ltd | Insulin preparation for intranasal administration |
| US4165370A (en) | 1976-05-21 | 1979-08-21 | Coval M L | Injectable gamma globulin |
| JPS6033474B2 (ja) | 1978-05-11 | 1985-08-02 | 藤沢薬品工業株式会社 | 新規なヒアルロニダ−ゼｂｍｐ−８２３１およびその製造法 |
| US4783441A (en) | 1979-04-30 | 1988-11-08 | Hoechst Aktiengesellschaft | Aqueous protein solutions stable to denaturation |
| DE3064888D1 (en) | 1979-04-30 | 1983-10-27 | Hoechst Ag | Aqueous solutions of proteins stable against denaturization, process for their manufacture, and their utilization |
| JPS55153712A (en) | 1979-05-18 | 1980-11-29 | Kao Corp | Insulin pharmaceutical preparation and its production |
| DE3033127A1 (de) | 1980-09-03 | 1982-04-08 | Hoechst Ag, 6000 Frankfurt | Neue analoga des insulins |
| US4367737A (en) | 1981-04-06 | 1983-01-11 | George Kozam | Multiple barrel syringe |
| WO1983000288A1 (en) | 1981-07-17 | 1983-02-03 | Balschmidt, Per | A stable aqueous, therapeutic insulin preparation and a process for preparing it |
| NL193099C (nl) | 1981-10-30 | 1998-11-03 | Novo Industri As | Gestabiliseerde insuline-oplossing. |
| DE3326473A1 (de) | 1983-07-22 | 1985-01-31 | Hoechst Ag, 6230 Frankfurt | Pharmazeutisches mittel zur behandlung des diabetes mellitus |
| DE3326472A1 (de) | 1983-07-22 | 1985-02-14 | Hoechst Ag, 6230 Frankfurt | Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus |
| DE3327709A1 (de) | 1983-07-29 | 1985-02-07 | Hoechst Ag, 6230 Frankfurt | Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung |
| DE3333640A1 (de) | 1983-09-17 | 1985-04-25 | Hoechst Ag, 6230 Frankfurt | Verfahren zur herstellung von insulin-derivaten, deren b-kette c-terminal verlaengert ist, neue basisch modifizierte insulin-derivate diese enthaltende mittel und ihre verwendung |
| US4839341A (en) | 1984-05-29 | 1989-06-13 | Eli Lilly And Company | Stabilized insulin formulations |
| CA1244347A (en) | 1984-05-29 | 1988-11-08 | Eddie H. Massey | Stabilized insulin formulations |
| DE3576120D1 (de) | 1984-06-09 | 1990-04-05 | Hoechst Ag | Insulinzubereitungen, verfahren zu deren herstellung und deren verwendung. |
| DE3440988A1 (de) | 1984-11-09 | 1986-07-10 | Hoechst Ag, 6230 Frankfurt | Verfahren zur spaltung von peptiden und proteinen an der methionyl-bindung |
| DK113585D0 (da) | 1985-03-12 | 1985-03-12 | Novo Industri As | Nye peptider |
| DK347086D0 (da) | 1986-07-21 | 1986-07-21 | Novo Industri As | Novel peptides |
| US5008241A (en) | 1985-03-12 | 1991-04-16 | Novo Nordisk A/S | Novel insulin peptides |
| EP0200383A3 (en) | 1985-04-15 | 1987-09-02 | Eli Lilly And Company | An improved method for administering insulin |
| US4689042A (en) | 1985-05-20 | 1987-08-25 | Survival Technology, Inc. | Automatic medicament ingredient mixing and injecting apparatus |
| DE3526995A1 (de) | 1985-07-27 | 1987-02-05 | Hoechst Ag | Fusionsproteine, verfahren zu ihrer herstellung und ihre verwendung |
| PH25772A (en) | 1985-08-30 | 1991-10-18 | Novo Industri As | Insulin analogues, process for their preparation |
| US4960702A (en) | 1985-09-06 | 1990-10-02 | Codon | Methods for recovery of tissue plasminogen activator |
| DE3541856A1 (de) | 1985-11-27 | 1987-06-04 | Hoechst Ag | Eukaryotische fusionsproteine, ihre herstellung und verwendung sowie mittel zur durchfuehrung des verfahrens |
| DE3636903A1 (de) | 1985-12-21 | 1987-07-02 | Hoechst Ag | Fusionsproteine mit eukaryotischem ballastanteil |
| US5496924A (en) | 1985-11-27 | 1996-03-05 | Hoechst Aktiengesellschaft | Fusion protein comprising an interleukin-2 fragment ballast portion |
| CA1275922C (en) | 1985-11-28 | 1990-11-06 | Harunobu Amagase | Treatment of cancer |
| DE3544295A1 (de) | 1985-12-14 | 1987-06-19 | Bayer Ag | Thermoplastische formmassen mit hoher kriechstromfestigkeit |
| US5614492A (en) | 1986-05-05 | 1997-03-25 | The General Hospital Corporation | Insulinotropic hormone GLP-1 (7-36) and uses thereof |
| PH23446A (en) | 1986-10-20 | 1989-08-07 | Novo Industri As | Peptide preparations |
| WO1988006599A1 (en) | 1987-02-25 | 1988-09-07 | Novo Industri A/S | Novel insulin derivatives |
| US5034415A (en) | 1987-08-07 | 1991-07-23 | Century Laboratories, Inc. | Treatment of diabetes mellitus |
| DE3726655A1 (de) | 1987-08-11 | 1989-02-23 | Hoechst Ag | Verfahren zur isolierung basischer proteine aus proteingemischen, welche solche basischen proteine enthalten |
| DK257988D0 (da) | 1988-05-11 | 1988-05-11 | Novo Industri As | Nye peptider |
| US6875589B1 (en) | 1988-06-23 | 2005-04-05 | Hoechst Aktiengesellschaft | Mini-proinsulin, its preparation and use |
| DE3827533A1 (de) | 1988-08-13 | 1990-02-15 | Hoechst Ag | Pharmazeutische zubereitung zur behandlung des diabetes mellitus |
| US4923162A (en) | 1988-09-19 | 1990-05-08 | Fleming Matthew C | Radiation shield swivel mount |
| DE3837825A1 (de) | 1988-11-08 | 1990-05-10 | Hoechst Ag | Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung |
| US5225323A (en) | 1988-11-21 | 1993-07-06 | Baylor College Of Medicine | Human high-affinity neurotransmitter uptake system |
| HUT56857A (en) | 1988-12-23 | 1991-10-28 | Novo Nordisk As | Human insulin analogues |
| US4994439A (en) | 1989-01-19 | 1991-02-19 | California Biotechnology Inc. | Transmembrane formulations for drug administration |
| IL93282A (en) | 1989-02-09 | 1995-08-31 | Lilly Co Eli | Insulin analogues |
| US5514646A (en) | 1989-02-09 | 1996-05-07 | Chance; Ronald E. | Insulin analogs modified at position 29 of the B chain |
| DK134189D0 (da) | 1989-03-20 | 1989-03-20 | Nordisk Gentofte | Insulinforbindelser |
| WO1990013361A1 (en) | 1989-05-04 | 1990-11-15 | Southern Research Institute | Improved encapsulation process and products therefrom |
| US5227293A (en) | 1989-08-29 | 1993-07-13 | The General Hospital Corporation | Fusion proteins, their preparation and use |
| US5358857A (en) | 1989-08-29 | 1994-10-25 | The General Hospital Corp. | Method of preparing fusion proteins |
| IL95495A (en) | 1989-08-29 | 1996-10-16 | Hoechst Ag | Fusion proteins their preparation and use |
| US5545618A (en) | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
| CN1020944C (zh) | 1990-01-30 | 1993-05-26 | 阿图尔-费希尔股份公司费希尔厂 | 紧固件 |
| US5397771A (en) | 1990-05-10 | 1995-03-14 | Bechgaard International Research And Development A/S | Pharmaceutical preparation |
| AU7880991A (en) | 1990-05-10 | 1991-11-27 | Novo Nordisk A/S | A pharmaceutical preparation containing n-glycofurols and n-ethylene glycols |
| DK155690D0 (da) | 1990-06-28 | 1990-06-28 | Novo Nordisk As | Nye peptider |
| DK10191D0 (da) | 1991-01-22 | 1991-01-22 | Novo Nordisk As | Hidtil ukendte peptider |
| US5272135A (en) | 1991-03-01 | 1993-12-21 | Chiron Ophthalmics, Inc. | Method for the stabilization of methionine-containing polypeptides |
| CA2038597A1 (en) | 1991-03-19 | 1992-09-20 | Jose P. Garzaran | A method and a pharmaceutical preparation for treating pain |
| US5614219A (en) | 1991-12-05 | 1997-03-25 | Alfatec-Pharma Gmbh | Oral administration form for peptide pharmaceutical substances, in particular insulin |
| US6468959B1 (en) | 1991-12-05 | 2002-10-22 | Alfatec-Pharm Gmbh | Peroral dosage form for peptide containing medicaments, in particular insulin |
| US5197926A (en) | 1992-02-18 | 1993-03-30 | Hedstrom Corporation | Swing connection guard |
| CH682806A5 (de) | 1992-02-21 | 1993-11-30 | Medimpex Ets | Injektionsgerät. |
| CH682805A5 (de) | 1992-02-24 | 1993-11-30 | Medimpex Ets | Anzeigeeinrichtung für ein Injektionsgerät. |
| DK36392D0 (da) | 1992-03-19 | 1992-03-19 | Novo Nordisk As | Anvendelse af kemisk forbindelse |
| US5846747A (en) | 1992-03-25 | 1998-12-08 | Novo Nordisk A/S | Method for detecting glucagon-like peptide-1 antagonists and agonists |
| DK39892D0 (da) | 1992-03-25 | 1992-03-25 | Bernard Thorens | Peptid |
| US5253785A (en) | 1992-04-02 | 1993-10-19 | Habley Medical Technology Corp. | Variable proportion dispenser |
| DK0600372T3 (da) | 1992-12-02 | 1997-08-11 | Hoechst Ag | Fremgangsmåde til fremstilling af proinsulin med korrekt forbundne cystinbroer. |
| MX9307991A (es) | 1992-12-18 | 1994-08-31 | Lilly Co Eli | Analogos de insulina, procedimiento para su preparacion y formulaciones farmaceuticas que los incluyen. |
| US5358708A (en) | 1993-01-29 | 1994-10-25 | Schering Corporation | Stabilization of protein formulations |
| US5478323A (en) | 1993-04-02 | 1995-12-26 | Eli Lilly And Company | Manifold for injection apparatus |
| US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
| DE69416409T2 (de) | 1993-06-21 | 1999-09-16 | Novo Nordisk A/S, Bagsvaerd | Asp-b28-insulinkristalle |
| US5506203C1 (en) | 1993-06-24 | 2001-02-06 | Astra Ab | Systemic administration of a therapeutic preparation |
| US5534488A (en) | 1993-08-13 | 1996-07-09 | Eli Lilly And Company | Insulin formulation |
| ATE212830T1 (de) | 1993-11-19 | 2002-02-15 | Alkermes Inc | Herstellung biologisch abbaubarer, einen biologisch aktiven stoff enthaltender, mikropartikel |
| US5705483A (en) | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
| IT1265271B1 (it) | 1993-12-14 | 1996-10-31 | Alcatel Italia | Sistema di predistorsione in banda base per la linearizzazione adattativa di amplificatori di potenza |
| US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| DE4405179A1 (de) | 1994-02-18 | 1995-08-24 | Hoechst Ag | Verfahren zur Gewinnung von Insulin mit korrekt verbundenen Cystinbrücken |
| DE4405388A1 (de) | 1994-02-19 | 1995-08-24 | Hoechst Ag | Verfahren zur Herstellung von Polyalkyl-1-oxa-diazaspirodecan-Verbindungen |
| CZ295827B6 (cs) | 1994-03-07 | 2005-11-16 | Nektar Therapeutics | Způsob aerosolizace dávky inzulinu, inzulinový přípravek a jeho použití |
| US5474978A (en) | 1994-06-16 | 1995-12-12 | Eli Lilly And Company | Insulin analog formulations |
| US5559094A (en) | 1994-08-02 | 1996-09-24 | Eli Lilly And Company | AspB1 insulin analogs |
| KR100356550B1 (ko) | 1994-09-09 | 2002-12-18 | 다케다 야쿠힌 고교 가부시키가이샤 | 펩티드의금속염을함유한서방성제제 |
| US5879584A (en) | 1994-09-10 | 1999-03-09 | The Procter & Gamble Company | Process for manufacturing aqueous compositions comprising peracids |
| US5547929A (en) | 1994-09-12 | 1996-08-20 | Eli Lilly And Company | Insulin analog formulations |
| US5766582A (en) | 1994-10-11 | 1998-06-16 | Schering Corporation | Stable, aqueous alfa interferon solution formulations |
| US5707641A (en) | 1994-10-13 | 1998-01-13 | Pharmaderm Research & Development Ltd. | Formulations comprising therapeutically-active proteins or polypeptides |
| AR002976A1 (es) | 1995-03-31 | 1998-05-27 | Lilly Co Eli | Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas |
| US5990077A (en) | 1995-04-14 | 1999-11-23 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
| IL118127A0 (en) | 1995-05-05 | 1996-09-12 | Lilly Co Eli | Single chain insulin with high bioactivity |
| US5824638A (en) | 1995-05-22 | 1998-10-20 | Shire Laboratories, Inc. | Oral insulin delivery |
| US6143718A (en) | 1995-06-07 | 2000-11-07 | Amylin Pharmaceuticals, Inc. | Treatment of Type II diabetes mellutis with amylin agonists |
| AU6011496A (en) | 1995-06-08 | 1997-01-09 | Therexsys Limited | Improved pharmaceutical compositions for gene therapy |
| DE69632684T2 (de) | 1995-06-27 | 2005-06-09 | Takeda Pharmaceutical Co. Ltd. | Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung |
| JPH11292787A (ja) | 1995-08-15 | 1999-10-26 | Asahi Chem Ind Co Ltd | 生理活性ペプチドを含有する経粘膜投与製剤 |
| DE19545257A1 (de) | 1995-11-24 | 1997-06-19 | Schering Ag | Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln |
| US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| DE19637230A1 (de) | 1996-09-13 | 1998-03-19 | Boehringer Mannheim Gmbh | Exendin-Analoga, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel |
| CN1183158C (zh) | 1996-06-05 | 2005-01-05 | 罗赫诊断器材股份有限公司 | Exendin类似物,其制备方法及含有它们的药物制剂 |
| US5948751A (en) | 1996-06-20 | 1999-09-07 | Novo Nordisk A/S | X14-mannitol |
| BR9709845B1 (pt) | 1996-06-20 | 2008-11-18 | preparaÇço aquosa de insulina, formulaÇço farmacÊutica parenteral, e, processso para aumentar a estabilidade quÍmica de uma preparaÇço de insulina. | |
| JP4472027B2 (ja) | 1996-06-20 | 2010-06-02 | ノボ ノルディスク アクティーゼルスカブ | 炭水化物含有インスリン製剤 |
| US6110703A (en) | 1996-07-05 | 2000-08-29 | Novo Nordisk A/S | Method for the production of polypeptides |
| AU4063697A (en) | 1996-08-08 | 1998-02-25 | Amylin Pharmaceuticals, Inc. | Methods for regulating gastrointestinal motility |
| AU752411B2 (en) | 1996-08-13 | 2002-09-19 | Genentech Inc. | Formulation |
| US5783556A (en) | 1996-08-13 | 1998-07-21 | Genentech, Inc. | Formulated insulin-containing composition |
| US6277819B1 (en) | 1996-08-30 | 2001-08-21 | Eli Lilly And Company | Use of GLP-1 or analogs in treatment of myocardial infarction |
| US6006753A (en) | 1996-08-30 | 1999-12-28 | Eli Lilly And Company | Use of GLP-1 or analogs to abolish catabolic changes after surgery |
| IL128332A0 (en) | 1996-08-30 | 2000-01-31 | Novo Nordisk As | GLP-1 derivatives |
| US6268343B1 (en) | 1996-08-30 | 2001-07-31 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| UA65549C2 (uk) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
| ATE304864T1 (de) | 1997-01-07 | 2005-10-15 | Amylin Pharmaceuticals Inc | Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme |
| US7312196B2 (en) | 1997-01-08 | 2007-12-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
| US6410511B2 (en) | 1997-01-08 | 2002-06-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
| JP2001512307A (ja) | 1997-02-05 | 2001-08-21 | １１４９３３６ オンタリオ インコーポレーテッド | プロエキセンジンをコードするポリヌクレオチドならびにその作製方法および使用 |
| US5846937A (en) | 1997-03-03 | 1998-12-08 | 1149336 Ontario Inc. | Method of using exendin and GLP-1 to affect the central nervous system |
| US6310038B1 (en) | 1997-03-20 | 2001-10-30 | Novo Nordisk A/S | Pulmonary insulin crystals |
| AU742591B2 (en) | 1997-03-20 | 2002-01-10 | Novo Nordisk A/S | Zinc free insulin crystals for use in pulmonary compositions |
| US6043214A (en) | 1997-03-20 | 2000-03-28 | Novo Nordisk A/S | Method for producing powder formulation comprising an insulin |
| CO4750643A1 (es) | 1997-06-13 | 1999-03-31 | Lilly Co Eli | Formulacion estable de la insulina que contiene l-arginina y protamina |
| EP0999853B1 (en) | 1997-06-13 | 2003-01-02 | Genentech, Inc. | Stabilized antibody formulation |
| DE19726167B4 (de) | 1997-06-20 | 2008-01-24 | Sanofi-Aventis Deutschland Gmbh | Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung |
| PT1019077E (pt) | 1997-08-08 | 2008-02-21 | Amylin Pharmaceuticals Inc | Novos compostos agonistas de exendina |
| DE19735711C2 (de) | 1997-08-18 | 2001-04-26 | Aventis Pharma Gmbh | Verfahren zur Herstellung eines Vorläufers von Insulin oder Insulinderivaten mit korrekt verbundenen Cystinbrücken |
| CA2306905A1 (en) | 1997-10-24 | 1999-05-06 | Eli Lilly And Company | Fatty acid-acylated insulin analogs |
| US6444641B1 (en) | 1997-10-24 | 2002-09-03 | Eli Lilly Company | Fatty acid-acylated insulin analogs |
| ZA989744B (en) | 1997-10-31 | 2000-04-26 | Lilly Co Eli | Method for administering acylated insulin. |
| DE69826705T2 (de) | 1997-11-12 | 2006-02-23 | Alza Corp., Palo Alto | Verfahren zur dermalen verabreichung von polypeptiden |
| ATE381939T1 (de) | 1997-11-14 | 2008-01-15 | Amylin Pharmaceuticals Inc | Neuartige exendin agonisten |
| WO1999025728A1 (en) | 1997-11-14 | 1999-05-27 | Amylin Pharmaceuticals, Inc. | Novel exendin agonist compounds |
| JP2001525371A (ja) | 1997-12-05 | 2001-12-11 | イーライ・リリー・アンド・カンパニー | Ｇｌｐ−１製剤 |
| EP1044016B1 (en) | 1998-01-09 | 2005-03-16 | Novo Nordisk A/S | Stabilised insulin compositions |
| ATE366115T1 (de) | 1998-02-13 | 2007-07-15 | Amylin Pharmaceuticals Inc | Inotropische und diuretische effekte von exendin und glp-1 |
| EA003944B1 (ru) | 1998-02-23 | 2003-10-30 | Ньюрокрайн Байосайенсиз Инк. | Способы лечения диабета с помощью пептидных аналогов инсулина |
| WO1999043708A1 (en) | 1998-02-27 | 1999-09-02 | Novo Nordisk A/S | Glp-1 derivatives of glp-1 and exendin with protracted profile of action |
| IL138214A0 (en) | 1998-03-09 | 2001-10-31 | Zealand Pharmaceuticals As | Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
| DE69918070T2 (de) | 1998-03-13 | 2005-08-25 | Novo Nordisk A/S | Stabilisierte, wässrige Glukagonlösungen, enthaltend Detergenzien |
| CA2334222C (en) | 1998-06-05 | 2010-02-09 | Technion Research And Development Foundation Ltd. | Insulin supplemented infant formula |
| EP1119625B1 (en) | 1998-10-07 | 2005-06-29 | Medical College Of Georgia Research Institute, Inc. | Glucose-dependent insulinotropic peptide for use as an osteotropic hormone |
| US6284725B1 (en) | 1998-10-08 | 2001-09-04 | Bionebraska, Inc. | Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue |
| US6211144B1 (en) | 1998-10-16 | 2001-04-03 | Novo Nordisk A/S | Stable concentrated insulin preparations for pulmonary delivery |
| PL197504B1 (pl) | 1998-10-16 | 2008-04-30 | Novo Nordisk As | Trwałe stężone preparaty insulinowe do podawania do płuc |
| CN1323220A (zh) | 1998-10-16 | 2001-11-21 | 诺沃挪第克公司 | 用于肺送递的含有薄荷醇的胰岛素制剂 |
| EP1131089B1 (en) | 1998-11-18 | 2004-02-18 | Novo Nordisk A/S | Stable aqueous insulin preparations without phenol and cresol |
| US6489292B1 (en) | 1998-11-18 | 2002-12-03 | Novo Nordisk A/S | Stable aqueous insulin preparations without phenol and cresol |
| BRPI0007820B8 (pt) | 1999-01-14 | 2021-05-25 | Amylin Pharmaceuticals Llc | formulações farmacêuticas agonistas de exendina e seus usos |
| DE19908041A1 (de) | 1999-02-24 | 2000-08-31 | Hoecker Hartwig | Kovalent verbrückte Insulindimere |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| JP2000247903A (ja) | 1999-03-01 | 2000-09-12 | Chugai Pharmaceut Co Ltd | 長期安定化製剤 |
| JP2007204498A (ja) | 1999-03-01 | 2007-08-16 | Chugai Pharmaceut Co Ltd | 長期安定化製剤 |
| US6227819B1 (en) | 1999-03-29 | 2001-05-08 | Walbro Corporation | Fuel pumping assembly |
| US6271241B1 (en) | 1999-04-02 | 2001-08-07 | Neurogen Corporation | Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors |
| BR0010705A (pt) | 1999-04-30 | 2002-02-05 | Amylin Pharmaceuticals Inc | Exendinas modificadas e agonistas da exendina |
| DE60006100T2 (de) | 1999-05-17 | 2004-07-01 | Conjuchem, Inc., Montreal | Lang wirkende insulinotrope peptide |
| AU5936400A (en) | 1999-06-04 | 2000-12-28 | Delrx Pharmaceutical Corporation | Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same |
| US6344180B1 (en) | 1999-06-15 | 2002-02-05 | Bionebraska, Inc. | GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes |
| CA2369839A1 (en) | 1999-06-25 | 2001-01-04 | Minimed, Inc. | Compositions of insulin and insulin-related peptide for treating diabetes |
| US6309663B1 (en) | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
| DE19930631A1 (de) | 1999-07-02 | 2001-01-11 | Clemens Micheler | Spritzvorrichtung zur Injektion mindestens zweier flüssiger Therapeutika, insbesondere Insuline |
| US6528486B1 (en) | 1999-07-12 | 2003-03-04 | Zealand Pharma A/S | Peptide agonists of GLP-1 activity |
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| WO2001021154A2 (en) | 1999-09-21 | 2001-03-29 | Rtp Pharma Inc. | Surface modified particulate compositions of biologically active substances |
| DE19947456A1 (de) | 1999-10-02 | 2001-04-05 | Aventis Pharma Gmbh | C-Peptid zur verbesserten Herstellung von Insulin und Insulinanaloga |
| CZ305123B6 (cs) | 1999-10-04 | 2015-05-13 | Novartis Vaccines And Diagnostics, Inc. | Způsob výroby kapalného farmaceutického prostředku |
| US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
| IL149139A0 (en) | 1999-11-03 | 2002-11-10 | Bristol Myers Squibb Co | Pharmaceutical compositions containing metformin and glyburide |
| BR0016334A (pt) | 1999-12-16 | 2002-09-10 | Lilly Co Eli | Composições de polipeptìdeo com estabilidade aperfeiçoada |
| EP1523993A1 (en) | 1999-12-16 | 2005-04-20 | Eli Lilly & Company | Polypeptide compositions with improved stability |
| US7022674B2 (en) | 1999-12-16 | 2006-04-04 | Eli Lilly And Company | Polypeptide compositions with improved stability |
| US20010012829A1 (en) | 2000-01-11 | 2001-08-09 | Keith Anderson | Transepithelial delivery GLP-1 derivatives |
| AU2353701A (en) | 2000-01-11 | 2001-07-24 | Novo Nordisk A/S | Transepithelial delivery of glp-1 derivatives |
| WO2001052937A1 (en) | 2000-01-24 | 2001-07-26 | Medtronic Minimed, Inc. | Mixed buffer system for stabilizing polypeptide formulations |
| US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
| AU2001264789A1 (en) | 2000-06-08 | 2001-12-17 | Eli Lilly And Company | Protein powder for pulmonary delivery |
| US6689353B1 (en) | 2000-06-28 | 2004-02-10 | Bayer Pharmaceuticals Corporation | Stabilized interleukin 2 |
| AU2001280436A1 (en) | 2000-07-12 | 2002-01-21 | Eli Lilly And Company | Process to increase protein stability |
| DK1326630T3 (da) | 2000-09-18 | 2008-09-15 | Sanos Bioscience As | Anvendelse af GLP-2-peptider |
| KR100508695B1 (ko) | 2001-02-13 | 2005-08-17 | 한국과학기술연구원 | 인슐린의 경구투여용 제형과 그의 제조방법 |
| US7060675B2 (en) | 2001-02-15 | 2006-06-13 | Nobex Corporation | Methods of treating diabetes mellitus |
| DE10108211A1 (de) | 2001-02-20 | 2002-08-22 | Aventis Pharma Gmbh | Verwendung von Fusionsproteinen, deren N-terminaler Anteil aus einem Hirudinderivat besteht, zur Herstellung rekombinanter Proteine über Sekretion durch Hefen |
| DE10108212A1 (de) | 2001-02-20 | 2002-08-22 | Aventis Pharma Gmbh | Fusionsprotein zur Sekretion von Wertprotein in bakterielle Überstände |
| DE10108100A1 (de) | 2001-02-20 | 2002-08-29 | Aventis Pharma Gmbh | Verwendung supersekretierbarer Peptide in Verfahren zu deren Herstellung und paralleler Verbesserung der Exportate eines oder mehrerer anderer Polypeptide von Interesse |
| WO2002067969A2 (en) | 2001-02-21 | 2002-09-06 | Medtronic Minimed, Inc. | Stabilized insulin formulations |
| WO2002067868A2 (en) | 2001-02-26 | 2002-09-06 | Millennium Pharmaceuticals, Inc. | Methods for the treatment of metabolic disorders, including obesity and diabetes |
| DE10114178A1 (de) | 2001-03-23 | 2002-10-10 | Aventis Pharma Gmbh | Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität |
| ATE443082T1 (de) | 2001-04-02 | 2009-10-15 | Novo Nordisk As | Insulinvorstufen und verfahren zu deren herstellung |
| CN1160122C (zh) | 2001-04-20 | 2004-08-04 | 清华大学 | 一种制备口服胰岛素油相制剂的方法 |
| US20030026872A1 (en) | 2001-05-11 | 2003-02-06 | The Procter & Gamble Co. | Compositions having enhanced aqueous solubility and methods of their preparation |
| US6737401B2 (en) | 2001-06-28 | 2004-05-18 | Metronic Minimed, Inc. | Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom |
| US7156877B2 (en) | 2001-06-29 | 2007-01-02 | The Regents Of The University Of California | Biodegradable/bioactive nucleus pulposus implant and method for treating degenerated intervertebral discs |
| FR2827604B1 (fr) | 2001-07-17 | 2003-09-19 | Sanofi Synthelabo | Nouveaux derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2- one, un procede pour leur preparation et les compositions pharmaceutiques en contenant |
| AU2002317599B2 (en) | 2001-07-31 | 2008-04-03 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | GLP-1 exendin-4 peptide analogs and uses thereof |
| WO2003020201A2 (en) | 2001-08-28 | 2003-03-13 | Eli Lilly And Company | Pre-mixes of glp-1 and basal insulin |
| WO2003035051A2 (en) | 2001-10-19 | 2003-05-01 | Inhale Therapeutic Systems, Inc. | The use of proton sequestering agents in drug formulations |
| WO2003035028A1 (en) | 2001-10-19 | 2003-05-01 | Nektar Therapeutics | Modulating charge density to produce improvements in the characteristics of spray-dried proteins |
| IL161358A0 (en) | 2001-11-19 | 2004-09-27 | Novo Nordisk As | Process for preparing insulin compounds |
| AU2002366803A1 (en) | 2001-12-19 | 2003-07-09 | Millennium Pharmaceuticals, Inc. | Human diacylglycerol acyltransferase 2 (dgat2) family members and uses therefor |
| BR0215029A (pt) | 2001-12-20 | 2005-12-20 | Lilly Co Eli | Molécula de insulina, uso da mesma, composição, uso desta, microcristal, processo para prepará-lo, uso deste, e, métodos para preparar uma molécula de insulina, para tratar hiperglicemia, e para tratar diabetes mellitus |
| CA2470511C (en) | 2001-12-21 | 2014-05-27 | Novo Nordisk Health Care Ag | Liquid composition of factor vii polypeptides |
| US8058233B2 (en) | 2002-01-10 | 2011-11-15 | Oregon Health And Science University | Modification of feeding behavior using PYY and GLP-1 |
| WO2003066084A1 (en) | 2002-02-07 | 2003-08-14 | Novo Nordisk A/S | Use of glp-1 compound for treatment of critically ill patients |
| US20100069293A1 (en) | 2002-02-27 | 2010-03-18 | Pharmain Corporation | Polymeric carrier compositions for delivery of active agents, methods of making and using the same |
| TWI351278B (en) | 2002-03-01 | 2011-11-01 | Nisshin Pharma Inc | Agent for preventing and treating of liver disease |
| WO2003094951A1 (en) | 2002-05-07 | 2003-11-20 | Novo Nordisk A/S | Soluble formulations comprising insulin aspart and insulin detemir |
| ATE496064T1 (de) | 2002-05-07 | 2011-02-15 | Novo Nordisk As | Lösliche formulierungen, die monomeres insulin und acyliertes insulin enthalten |
| US7115563B2 (en) | 2002-05-29 | 2006-10-03 | Insignion Holding Limited | Composition and its therapeutic use |
| US20040022792A1 (en) | 2002-06-17 | 2004-02-05 | Ralph Klinke | Method of stabilizing proteins at low pH |
| DE10227232A1 (de) | 2002-06-18 | 2004-01-15 | Aventis Pharma Deutschland Gmbh | Saure Insulinzubereitungen mit verbesserter Stabilität |
| ES2327328T3 (es) | 2002-07-04 | 2009-10-28 | Zealand Pharma A/S | Glp-1 y procedimientos para el tratamiento de la diabetes. |
| DE10235168A1 (de) | 2002-08-01 | 2004-02-12 | Aventis Pharma Deutschland Gmbh | Verfahren zur Reinigung von Preproinsulin |
| EP2384750A1 (en) | 2002-09-27 | 2011-11-09 | Martek Biosciences Corporation | Improved Glycemic Control for Prediabetes and/or Diabetes Type II using Docohexaenoic Acid |
| CA2500295A1 (en) | 2002-10-02 | 2004-04-29 | Zealand Pharma A/S | Stabilized exendin-4 compounds |
| US6969702B2 (en) | 2002-11-20 | 2005-11-29 | Neuronova Ab | Compounds and methods for increasing neurogenesis |
| US20050209142A1 (en) | 2002-11-20 | 2005-09-22 | Goran Bertilsson | Compounds and methods for increasing neurogenesis |
| DE60335743D1 (de) | 2002-11-20 | 2011-02-24 | Neuronova Ab | Verbindungen und verfahren zur erhöhung der neurogenese |
| CN1413582A (zh) | 2002-11-29 | 2003-04-30 | 贵州圣济堂制药有限公司 | 盐酸二甲双胍肠溶片及其制备方法 |
| EP1569682A2 (en) | 2002-12-03 | 2005-09-07 | Novo Nordisk A/S | Combination treatment using exendin-4 and thiazolidinediones |
| GB0309154D0 (en) | 2003-01-14 | 2003-05-28 | Aventis Pharma Inc | Use of insulin glargine to reduce or prevent cardiovascular events in patients being treated for dysglycemia |
| GB0304822D0 (en) | 2003-03-03 | 2003-04-09 | Dca Internat Ltd | Improvements in and relating to a pen-type injector |
| DE602004029630D1 (de) | 2003-03-04 | 2010-12-02 | Technology Dev Co Ltd | Injizierbare Insulinzubereitung mit Langzeitwirkung und Verfahren zur dessen Herstellung und Verwendung |
| BRPI0408229A (pt) | 2003-03-11 | 2006-02-21 | Novo Nordisk As | preparação farmacêutica, métodos para preparar um ligando de ligação de zinco, para prolongar a ação de uma preparação de insulina estabilizada por ácido e para tratar diabete do tipo 1 ou tipo 2, e, uso de uma preparação |
| US20040186046A1 (en) | 2003-03-17 | 2004-09-23 | Pfizer Inc | Treatment of type 1 diabetes with PDE5 inhibitors |
| BRPI0409600A (pt) | 2003-04-29 | 2006-04-18 | Lilly Co Eli | análogo de insulina, composição, método de tratamento de hiperglicemia, e, análogo de pró-insulina |
| EP1633390B1 (en) | 2003-06-03 | 2012-01-18 | Novo Nordisk A/S | Stabilized pharmaceutical glp-1 peptide compositions |
| DE10325567B4 (de) | 2003-06-05 | 2008-03-13 | Mavig Gmbh | Strahlenschutzanordnung mit separierbarer Umhüllung |
| CA2542372A1 (en) | 2003-08-29 | 2005-03-10 | Centocor, Inc. | Method of promoting graft survival with anti-tissue factor antibodies |
| WO2005021022A2 (en) | 2003-09-01 | 2005-03-10 | Novo Nordisk A/S | Stable formulations of peptides |
| WO2005023291A2 (en) | 2003-09-11 | 2005-03-17 | Novo Nordisk A/S | Use of glp1-agonists in the treatment of patients with type i diabetes |
| EP1667724A2 (en) | 2003-09-19 | 2006-06-14 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
| US20060287221A1 (en) | 2003-11-13 | 2006-12-21 | Novo Nordisk A/S | Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia |
| ATE525083T1 (de) | 2003-11-13 | 2011-10-15 | Novo Nordisk As | Pharmazeutische zusammensetzung umfassend eine insulinotrope glp-1(7-37) analoge, asp(b28)- insulin, und eine oberflächenaktive verbindung |
| US20050201978A1 (en) | 2003-11-17 | 2005-09-15 | Lipton James S. | Tumor and infectious disease therapeutic compositions |
| EP1699629B1 (en) | 2003-12-22 | 2010-10-06 | Novo Nordisk A/S | Transparent, flexible , impermeable plastic container for storage of pharmaceutical liquids |
| US20060210614A1 (en) | 2003-12-26 | 2006-09-21 | Nastech Pharmaceutical Company Inc. | Method of treatment of a metabolic disease using intranasal administration of exendin peptide |
| US7192919B2 (en) | 2004-01-07 | 2007-03-20 | Stelios Tzannis | Sustained release compositions for delivery of pharmaceutical proteins |
| US20070027063A1 (en) | 2004-01-12 | 2007-02-01 | Mannkind Corporation | Method of preserving the function of insulin-producing cells |
| US20080090753A1 (en) | 2004-03-12 | 2008-04-17 | Biodel, Inc. | Rapid Acting Injectable Insulin Compositions |
| US20080248999A1 (en) | 2007-04-04 | 2008-10-09 | Biodel Inc. | Amylin formulations |
| KR20070004078A (ko) | 2004-03-31 | 2007-01-05 | 센토코 인코포레이티드 | 인간 ｇｌｐ-1 모방체, 조성물, 방법 및 용도 |
| US8673964B2 (en) | 2004-05-20 | 2014-03-18 | Diamedica Inc. | Use of drug combinations for treating insulin resistance |
| ZA200610041B (en) | 2004-06-01 | 2008-07-30 | Ares Trading Sa | Method of stabilizing proteins |
| EA200700117A1 (ru) | 2004-06-24 | 2007-06-29 | Инсайт Корпорейшн | N-замещенные пиперидины и их применение в качестве фармацевтических препаратов |
| US20090042781A1 (en) | 2004-06-28 | 2009-02-12 | Novo Nordisk A/S | Methods for Treating Diabetes |
| US7638299B2 (en) | 2004-07-21 | 2009-12-29 | Ambrx, Inc. | Biosynthetic polypeptides utilizing non-naturally encoded amino acids |
| CN101014360A (zh) | 2004-08-03 | 2007-08-08 | 埃米斯菲尔技术公司 | 抗糖尿病口服胰岛素－双胍组合物 |
| CA2569707C (en) | 2004-08-13 | 2013-09-24 | F. Hoffmann-La Roche Ag | C-terminal modification of polypeptides |
| DE102004043153B4 (de) | 2004-09-03 | 2013-11-21 | Philipps-Universität Marburg | Erfindung betreffend GLP-1 und Exendin |
| US20060073213A1 (en) | 2004-09-15 | 2006-04-06 | Hotamisligil Gokhan S | Reducing ER stress in the treatment of obesity and diabetes |
| WO2006029634A2 (en) | 2004-09-17 | 2006-03-23 | Novo Nordisk A/S | Pharmaceutical compositions containing insulin and insulinotropic peptide |
| JP2006137678A (ja) | 2004-11-10 | 2006-06-01 | Shionogi & Co Ltd | インターロイキン−２組成物 |
| ES2575984T3 (es) | 2004-11-12 | 2016-07-04 | Novo Nordisk A/S | Formulaciones estables de péptidos que contienen un análogo de GLP-1 acilado y una insulina basal |
| JP5175103B2 (ja) | 2004-11-12 | 2013-04-03 | ノヴォ ノルディスク アー／エス | 安定なペプチド製剤 |
| DE102004058306A1 (de) | 2004-12-01 | 2006-07-27 | Sanofi-Aventis Deutschland Gmbh | Verfahren zur Herstellung von Carboxy-terminal amidierten Peptiden |
| SE0402976L (sv) | 2004-12-03 | 2006-06-04 | Mederio Ag | Medicinsk produkt |
| SG158158A1 (en) | 2004-12-22 | 2010-01-29 | Centocor Inc | Glp-1 agonists, compositions, methods and uses |
| US7879361B2 (en) | 2005-01-04 | 2011-02-01 | Gp Medical, Inc. | Nanoparticles for drug delivery |
| US20090142338A1 (en) | 2005-03-04 | 2009-06-04 | Curedm, Inc. | Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions |
| AU2006235183B2 (en) | 2005-04-08 | 2011-02-10 | Amylin Pharmaceuticals, Llc | Pharmaceutical formulations comprising incretin peptide and aprotic polar solvent |
| EP1888118B1 (en) | 2005-05-25 | 2016-08-17 | Novo Nordisk A/S | Polypeptide formulations stabilized with ethylenediamine |
| WO2006131730A1 (en) | 2005-06-06 | 2006-12-14 | Camurus Ab | Glp-1 analogue formulations |
| CN102036662B (zh) | 2005-06-27 | 2013-02-27 | 新树股份有限公司 | 利用肉豆蔻衣木脂素预防和治疗ppar介导的疾病的方法 |
| US20080227847A1 (en) | 2005-07-07 | 2008-09-18 | Aditech Pharma Ab | Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use |
| DK3524261T5 (da) | 2005-08-19 | 2024-09-02 | Amylin Pharmaceuticals Llc | Exendin til anvendelse til behandling af diabetes og reduktion af kropsvægt |
| WO2007028394A2 (en) | 2005-09-08 | 2007-03-15 | Gastrotech Pharma A/S | Use of a glp-1 molecule for treatment of biliary dyskinesia and/or biliary pain/discomfort |
| KR101304958B1 (ko) | 2005-09-14 | 2013-09-17 | 에프. 호프만-라 로슈 아게 | 트립신 변이체에 의한 인슐린 전구체의 절단 |
| JP5072848B2 (ja) | 2005-09-20 | 2012-11-14 | ノバルティス アーゲー | 低血糖イベントを低減するためのｄｐｐ−ｉｖ阻害剤の使用 |
| EP1945142B1 (en) | 2005-09-26 | 2013-12-25 | Medtronic, Inc. | Prosthetic cardiac and venous valves |
| DE102005046113A1 (de) | 2005-09-27 | 2007-03-29 | Sanofi-Aventis Deutschland Gmbh | Verfahren zur Amidierung von Polypetiden mit C-terminalen basischen Aminosäuren unter Verwendung spezifischer Endoproteasen |
| KR101105871B1 (ko) | 2005-09-27 | 2012-01-16 | 주식회사 엘지생명과학 | 인 난포자극호르몬의 안정한 용액 제형 |
| US8084420B2 (en) | 2005-09-29 | 2011-12-27 | Biodel Inc. | Rapid acting and long acting insulin combination formulations |
| WO2007044867A2 (en) | 2005-10-11 | 2007-04-19 | Huntington Medical Research Institutes | Imaging agents and methods of use thereof |
| US8530447B2 (en) | 2005-10-24 | 2013-09-10 | Nestec S.A. | Dietary fiber formulation and method of administration |
| CN101309668A (zh) | 2005-11-30 | 2008-11-19 | 健乐克斯医药公司 | 经口吸收的药物制剂和用药方法 |
| US20100029558A1 (en) | 2005-12-06 | 2010-02-04 | Bristow Cynthia L | Alpha1 proteinase inhibitor peptides methods and use |
| WO2007075534A2 (en) | 2005-12-16 | 2007-07-05 | Nektar Therapeutics Al, Corporation | Polymer conjugates of glp-1 |
| CA2636469A1 (en) | 2006-01-05 | 2007-07-19 | University Of Utah Research Foundation | Methods and compositions related to improving properties of pharmacological agents targeting nervous system |
| US8343914B2 (en) | 2006-01-06 | 2013-01-01 | Case Western Reserve University | Fibrillation resistant proteins |
| WO2007082381A1 (en) | 2006-01-20 | 2007-07-26 | Diamedica Inc. | Compositions containing (s)-bethanechol and their use in the treatment of insulin resistance, type 2 diabetes, glucose intolerance and related disorders |
| US20070191271A1 (en) | 2006-02-10 | 2007-08-16 | Dow Pharmaceutical Sciences | Method for stabilizing polypeptides lacking methionine |
| WO2007095288A2 (en) | 2006-02-13 | 2007-08-23 | Nektar Therapeutics | Methionine-containing protein or peptide compositions and methods of making and using |
| WO2007098479A2 (en) | 2006-02-21 | 2007-08-30 | University Of Medicine And Dentistry Of New Jersey | Localized insulin delivery for bone healing |
| EP1996224B1 (en) | 2006-03-15 | 2012-11-07 | Novo Nordisk A/S | Mixtures of amylin and insulin |
| TW200806317A (en) | 2006-03-20 | 2008-02-01 | Wyeth Corp | Methods for reducing protein aggregation |
| JP2009532422A (ja) | 2006-04-03 | 2009-09-10 | ノボ・ノルデイスク・エー／エス | Ｇｌｐ−１ペプチドアゴニスト |
| CN101454019A (zh) | 2006-04-12 | 2009-06-10 | 百达尔公司 | 速效和长效胰岛素联合制剂 |
| NZ571862A (en) | 2006-04-13 | 2011-10-28 | Ipsen Pharma Sas | Pharmaceutical composition comprising HGLP-1, a zinc divalent metal ion and a solvent |
| JP2009539778A (ja) | 2006-06-08 | 2009-11-19 | ダイアベコア メディカル インコーポレイテッド | インスリンオリゴマー誘導体 |
| DE102006031962A1 (de) | 2006-07-11 | 2008-01-17 | Sanofi-Aventis Deutschland Gmbh | Amidiertes Insulin Glargin |
| JP2009544716A (ja) | 2006-07-27 | 2009-12-17 | ノバルティス アクチエンゲゼルシャフト | 肺送達のためのインスリン含有エアロゾル化可能製剤 |
| AU2007284365A1 (en) | 2006-08-17 | 2008-02-21 | Amylin Pharmaceuticals, Inc. | DPP-IV resistant GIP hybrid polypeptides with selectable properties |
| US20090318353A1 (en) | 2006-08-25 | 2009-12-24 | Novo Nordisk A/S | Acylated Exendin-4 Compounds |
| NZ574710A (en) | 2006-09-07 | 2012-02-24 | Nycomed Gmbh | Combination treatment comprising the PDE4 inhibitor Compound A ((2R,4aR, 10bR)6-(2,6-Dimethoxy-pyridin-3-yl)-9-ethoxy-8-methoxy-1 ,2,3,4,4a,10b-hexahydrophenanthridin-2-ol) for diabetes mellitus |
| KR101729986B1 (ko) | 2006-09-22 | 2017-04-25 | 노보 노르디스크 에이/에스 | 프로테아제 내성 인슐린 유사체 |
| PL2157967T3 (pl) | 2007-04-23 | 2013-06-28 | Intarcia Therapeutics Inc | Formulacje zawiesinowe peptydów insulinotropowych i ich zastosowania |
| WO2008145323A1 (en) | 2007-05-31 | 2008-12-04 | F. Hoffmann-La Roche Ag | Pharmaceutical formulation for interferons |
| ES2386166T5 (es) | 2007-06-14 | 2016-06-21 | Sanofi-Aventis Deutschland Gmbh | Carpule de dos cámaras con accesorio |
| CN101678174A (zh) | 2007-06-14 | 2010-03-24 | 塞诺菲-安万特德国有限公司 | 双室卡普耳 |
| DK2173407T3 (da) | 2007-07-02 | 2020-04-27 | Hoffmann La Roche | Anordning til indgivelse af lægemiddel |
| AU2008287063B2 (en) | 2007-08-09 | 2013-10-24 | Genzyme Corporation | Method of treating autoimmune disease with mesenchymal stem cells |
| WO2009021955A1 (en) | 2007-08-13 | 2009-02-19 | Novo Nordisk A/S | Rapid acting insulin analogues |
| CN101366692A (zh) | 2007-08-15 | 2009-02-18 | 江苏豪森药业股份有限公司 | 一种稳定的艾塞那肽制剂 |
| GB0717388D0 (en) | 2007-09-07 | 2007-10-17 | Uutech Ltd | Use of GIP for the treatment of disorders associated with dysfunctional synaptic transmission |
| GB0717399D0 (en) | 2007-09-07 | 2007-10-17 | Uutech Ltd | Use of GLP-1 analogues for the treatment of disorders associated with dysfunctional synaptic transmission |
| CA2699257A1 (en) | 2007-09-11 | 2009-04-16 | Mondobiotech Laboratories Ag | Cgrp as a therapeutic agent |
| US20090104210A1 (en) | 2007-10-17 | 2009-04-23 | Tota Michael R | Peptide compounds for treating obesity and insulin resistance |
| JP5551601B2 (ja) | 2007-11-01 | 2014-07-16 | メルク セローノ ソシエテ アノニム | Ｌｈ液体調製物 |
| WO2009060071A1 (en) | 2007-11-08 | 2009-05-14 | Novo Nordisk A/S | Insulin derivative |
| US8937042B2 (en) | 2007-11-16 | 2015-01-20 | Novo Nordisk A/S | Pharmaceutical compositions comprising GLP-1 peptides or extendin-4 and a basal insulin peptide |
| CN101444618B (zh) | 2007-11-26 | 2012-06-13 | 杭州九源基因工程有限公司 | 含有艾塞那肽的药物制剂 |
| EP2231191A2 (en) | 2007-12-11 | 2010-09-29 | ConjuChem Biotechnologies Inc. | Formulation of insulinotropic peptide conjugates |
| EP2234644B1 (en) | 2008-01-04 | 2013-07-31 | Biodel, Inc. | Insulin formulations for insulin release as a function of tissue glucose levels |
| DE102008003566A1 (de) | 2008-01-09 | 2009-07-16 | Sanofi-Aventis Deutschland Gmbh | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
| MY152979A (en) | 2008-01-09 | 2014-12-15 | Sanofi Aventis Deutschland | Novel insulin derivatives having an extremely delayed time-action profile |
| DE102008003568A1 (de) | 2008-01-09 | 2009-07-16 | Sanofi-Aventis Deutschland Gmbh | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
| EP2229406B1 (de) | 2008-01-09 | 2015-04-22 | Sanofi-Aventis Deutschland GmbH | Neue insulinderivate mit extrem verzögertem zeit- / wirkungsprofil |
| US20110054410A1 (en) | 2008-02-08 | 2011-03-03 | Biogenerix Ag | Liquid formulation of fsh |
| CA2726861C (en) | 2008-02-13 | 2014-05-27 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
| MY161892A (en) | 2008-02-19 | 2017-05-15 | Biocon Ltd | A method of obtaining a purified, biologically active heterologous protein |
| TWI394580B (zh) | 2008-04-28 | 2013-05-01 | Halozyme Inc | 超快起作用胰島素組成物 |
| US8329419B2 (en) | 2008-05-23 | 2012-12-11 | Amylin Pharmaceuticals, Llc | GLP-1 receptor agonist bioassays |
| TWI451876B (zh) | 2008-06-13 | 2014-09-11 | Lilly Co Eli | 聚乙二醇化之離脯胰島素化合物 |
| CN105727261A (zh) | 2008-06-27 | 2016-07-06 | 杜克大学 | 包含弹性蛋白样肽的治疗剂 |
| US7986407B2 (en) | 2008-08-04 | 2011-07-26 | Ondax, Inc. | Method and apparatus using volume holographic wavelength blockers |
| JP5854836B2 (ja) | 2008-08-30 | 2016-02-09 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | カートリッジ及びそのための針システム |
| WO2010028055A1 (en) | 2008-09-02 | 2010-03-11 | Biodel, Inc. | Insulin with a basal release profile |
| EP2334323A2 (en) | 2008-09-10 | 2011-06-22 | F. Hoffmann-La Roche AG | Compositions and methods for the prevention of oxidative degradation of proteins |
| CN101670096B (zh) | 2008-09-11 | 2013-01-16 | 杭州九源基因工程有限公司 | 含有艾塞那肽的药物制剂 |
| EP2349200A1 (en) | 2008-10-15 | 2011-08-03 | Intarcia Therapeutics, Inc | Highly concentrated drug particles, formulations, suspensions and uses thereof |
| PL3228320T3 (pl) | 2008-10-17 | 2020-06-01 | Sanofi-Aventis Deutschland Gmbh | Kombinacja insuliny i agonisty GLP-1 |
| DE102008053048A1 (de) | 2008-10-24 | 2010-04-29 | Sanofi-Aventis Deutschland Gmbh | Kombination von einem Insulin und einem GLP-1-Agonisten |
| ES2607003T3 (es) | 2008-10-30 | 2017-03-28 | Novo Nordisk A/S | Tratamiento de diabetes mellitus utilizando inyecciones de insulina con una frecuencia de inyección inferior a la diaria |
| JP2009091363A (ja) | 2008-11-21 | 2009-04-30 | Asahi Kasei Pharma Kk | Ｐｔｈの安定化水溶液注射剤 |
| AR075204A1 (es) | 2009-01-29 | 2011-03-16 | Boehringer Ingelheim Int | Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2 |
| JP5677321B2 (ja) | 2009-02-04 | 2015-02-25 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 血糖コントロール用の情報を提供するための医療デバイス及び方法 |
| NZ594044A (en) | 2009-02-13 | 2014-08-29 | Boehringer Ingelheim Int | Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics |
| EP2435061A4 (en) | 2009-05-28 | 2013-03-27 | Amylin Pharmaceuticals Inc | DAMPING GLP-1 RECEPTOR AGONIST COMPOUNDS |
| TW201105346A (en) | 2009-07-06 | 2011-02-16 | Sanofi Aventis Deutschland | Heat-stable and vibration-stable insulin preparations |
| TWI520745B (zh) | 2009-07-06 | 2016-02-11 | 賽諾菲阿凡提斯德意志有限公司 | 含甲硫胺酸之胰島素製劑 |
| WO2011003823A1 (de) | 2009-07-06 | 2011-01-13 | Sanofi-Aventis Deutschland Gmbh | Langsamwirkende insulinzubereitungen |
| US8709400B2 (en) | 2009-07-27 | 2014-04-29 | Washington University | Inducement of organogenetic tolerance for pancreatic xenotransplant |
| NZ597964A (en) | 2009-07-31 | 2014-04-30 | Sanofi Aventis Deutschland | Long acting insulin composition |
| WO2011017554A2 (en) | 2009-08-07 | 2011-02-10 | Mannkind Corporation | Val (8) glp-1 composition and method for treating functional dyspepsia and/or irritable bowel syndrome |
| AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
| US20110118178A1 (en) | 2009-11-13 | 2011-05-19 | Sanofi-Aventis Deutschland Gmbh | Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin |
| CA3011480C (en) | 2009-11-13 | 2021-11-09 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine |
| SI2324853T1 (sl) | 2009-11-13 | 2015-12-31 | Sanofi-Aventis Deutschland Gmbh | Liksisenatid kot dodatek metforminu pri zdravljenju sladkorne bolezni tipa 2 |
| CA2685638C (en) | 2009-11-13 | 2017-02-28 | Sanofi-Aventis Deutschland Gmbh | Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin |
| SI2498801T1 (en) | 2009-11-13 | 2018-06-29 | Sanofi-Aventis Deutschland Gmbh | A pharmaceutical composition containing desPro36Exendin-4 (1-39) -Lys6-NH2 and methionine |
| US20110118180A1 (en) | 2009-11-13 | 2011-05-19 | Sanofi-Aventis Deutschland Gmbh | Method of treatment of diabetes type 2 comprising add-on therapy to metformin |
| ES2398012T5 (es) | 2009-11-13 | 2020-02-26 | Sanofi Aventis Deutschland | Lixisenatide como terapia complementaria a insulina glargina y metformina para tratar diabetes de tipo 2 |
| WO2011075623A1 (en) | 2009-12-18 | 2011-06-23 | Latitude Pharmaceuticals, Inc. | One - phase gel compos ition compri s ing phos pholi pids |
| EP2359843A1 (en) | 2010-01-21 | 2011-08-24 | Sanofi | Pharmaceutical composition for treating a metabolic syndrome |
| CA2790495A1 (en) | 2010-02-22 | 2011-08-25 | Case Western Reserve University | Long-acting insulin analogue preparations in soluble and crystalline forms |
| AR081066A1 (es) | 2010-04-02 | 2012-06-06 | Hanmi Holdings Co Ltd | Conjugado de insulina donde se usa un fragmento de inmunoglobulina |
| UY33326A (es) | 2010-04-14 | 2011-12-01 | Sanofi Aventis | Conjugados de insulina-sirna |
| US8637458B2 (en) | 2010-05-12 | 2014-01-28 | Biodel Inc. | Insulin with a stable basal release profile |
| AU2011202239C1 (en) * | 2010-05-19 | 2017-03-16 | Sanofi | Long-acting formulations of insulins |
| WO2011144674A2 (en) | 2010-05-20 | 2011-11-24 | Sanofi-Aventis Deutschland Gmbh | PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND SBE4-ß-CYD |
| EP2389945A1 (en) * | 2010-05-28 | 2011-11-30 | Sanofi-Aventis Deutschland GmbH | Pharmaceutical composition comprising AVE0010 and insulin glargine |
| US9085757B2 (en) | 2010-06-17 | 2015-07-21 | Regents Of The University Of Minnesota | Production of insulin producing cells |
| US8532933B2 (en) | 2010-06-18 | 2013-09-10 | Roche Diagnostics Operations, Inc. | Insulin optimization systems and testing methods with adjusted exit criterion accounting for system noise associated with biomarkers |
| US20130137645A1 (en) | 2010-07-19 | 2013-05-30 | Mary S. Rosendahl | Modified peptides and proteins |
| EP2611458B1 (en) | 2010-08-30 | 2016-09-21 | Sanofi-Aventis Deutschland GmbH | Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2 |
| CN103167878A (zh) | 2010-10-27 | 2013-06-19 | 诺沃—诺迪斯克有限公司 | 采用在不同注射时间间隔给予的胰岛素注射剂治疗糖尿病 |
| WO2012065996A1 (en) | 2010-11-15 | 2012-05-24 | Sanofi-Aventis Deutschland Gmbh | PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND MALTOSYL-ß-CYCLODEXTRIN |
| WO2012066086A1 (en) | 2010-11-17 | 2012-05-24 | Sanofi-Aventis Deutschland Gmbh | PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND SULFOBUTYL ETHER 7-ß-CYCLODEXTRIN |
| EP2651432A1 (en) | 2010-12-14 | 2013-10-23 | Novo Nordisk A/S | Fast-acting insulin in combination with long-acting insulin |
| TW201236692A (en) | 2011-02-02 | 2012-09-16 | Sanofi Aventis Deutschland | Prevention of hypoglycaemia in diabetes mellitus type 2 patients |
| ES2733646T3 (es) | 2011-03-11 | 2019-12-02 | Beth Israel Deaconess Medical Ct Inc | Anticuerpos anti-CD40 y usos de los mismos |
| US20120277147A1 (en) | 2011-03-29 | 2012-11-01 | Sanofi-Aventis Deutschland Gmbh | Prevention of hypoglycaemia in diabetes mellitus type 2 patients |
| US8735349B2 (en) | 2011-05-13 | 2014-05-27 | Sanofi-Aventis Deutschland Gmbh | Method for improving glucose tolerance in a diabetes type 2 patient of younger than 50 years and having postprandial plasma glucose concentration of at least 14 mmol/L |
| US20130040878A1 (en) | 2011-05-13 | 2013-02-14 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for use in the treatment of diabetes type 2 patients |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| ES2556466T3 (es) | 2011-05-13 | 2016-01-18 | Sanofi-Aventis Deutschland Gmbh | Lixisenatida y metformina para el tratamiento de la diabetes tipo 2 |
| JP2014520159A (ja) | 2011-06-24 | 2014-08-21 | アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー | Ｇｌｐ−１受容体アゴニストの徐放性製剤による糖尿病の治療方法 |
| EP2750699B1 (en) | 2011-08-29 | 2015-07-22 | Sanofi-Aventis Deutschland GmbH | Pharmaceutical combination for use in glycemic control in diabetes type 2 patients |
| TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
| EP2763691A1 (en) | 2011-10-04 | 2014-08-13 | Sanofi-Aventis Deutschland GmbH | Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the biliary tract |
| HRP20160171T1 (hr) | 2011-10-04 | 2016-03-11 | Sanofi-Aventis Deutschland Gmbh | Liksisenatid za uporabu u lijeäśenju stenoze i/ili opstrukcije u sustavu kanala gušteraäśe |
| SG11201401175SA (en) | 2011-10-28 | 2014-09-26 | Sanofi Aventis Deutschland | Treatment protocol of diabetes type 2 |
| US8901484B2 (en) | 2012-04-27 | 2014-12-02 | Sanofi-Aventis Deutschland Gmbh | Quantification of impurities for release testing of peptide products |
| US9522235B2 (en) | 2012-05-22 | 2016-12-20 | Kaleo, Inc. | Devices and methods for delivering medicaments from a multi-chamber container |
| AR092862A1 (es) | 2012-07-25 | 2015-05-06 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion |
| TWI780236B (zh) | 2013-02-04 | 2022-10-11 | 法商賽諾菲公司 | 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物 |
| CN105007931B (zh) | 2013-03-01 | 2018-04-06 | 瓦尔德西布伦大学医院基金会研究所 | 肽在视网膜神经退行性疾病，特别是在糖尿病视网膜病变早期和神经退行性变起重要作用的其它视网膜疾病的局部治疗中的应用 |
| GB201303771D0 (en) | 2013-03-04 | 2013-04-17 | Midatech Ltd | Nanoparticles peptide compositions |
| EP3010530B1 (en) | 2013-06-17 | 2018-12-26 | Sanofi-Aventis Deutschland GmbH | Insulin glargine/lixisenatide fixed ratio formulation |
| AR098168A1 (es) | 2013-10-25 | 2016-05-04 | Sanofi Sa | Formulación estable de insulina glulisina |
| PE20171622A1 (es) | 2014-12-12 | 2017-11-02 | Sanofi Aventis Deutschland | Formulacion de relacion fija de insulina glargina/lixisenatida |
| TWI706779B (zh) | 2015-01-16 | 2020-10-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 小兒第２型糖尿病病患之治療 |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| US10905707B2 (en) | 2017-11-10 | 2021-02-02 | University Of Massachusetts | Compositions and methods for the treatment of expanded repeat-associated disorders |
-
2015
- 2015-12-10 PE PE2017000990A patent/PE20171622A1/es not_active Application Discontinuation
- 2015-12-10 BR BR112017012406A patent/BR112017012406A2/pt not_active Application Discontinuation
- 2015-12-10 CR CR20170314A patent/CR20170314A/es unknown
- 2015-12-10 MA MA41138A patent/MA41138B1/fr unknown
- 2015-12-10 HU HUE15808177A patent/HUE062573T2/hu unknown
- 2015-12-10 US US14/965,586 patent/US9950039B2/en active Active
- 2015-12-10 FI FIEP15808177.8T patent/FI3229828T3/fi active
- 2015-12-10 MX MX2017007699A patent/MX389178B/es unknown
- 2015-12-10 SI SI201531944T patent/SI3229828T1/sl unknown
- 2015-12-10 LT LTEPPCT/EP2015/079285T patent/LT3229828T/lt unknown
- 2015-12-10 SG SG11201704678SA patent/SG11201704678SA/en unknown
- 2015-12-10 KR KR1020177019145A patent/KR102578030B1/ko active Active
- 2015-12-10 EP EP15808177.8A patent/EP3229828B1/en active Active
- 2015-12-10 HR HRP20230470TT patent/HRP20230470T1/hr unknown
- 2015-12-10 PL PL15808177.8T patent/PL3229828T3/pl unknown
- 2015-12-10 WO PCT/EP2015/079285 patent/WO2016092026A1/en not_active Ceased
- 2015-12-10 CA CA2970200A patent/CA2970200A1/en active Pending
- 2015-12-10 DK DK15808177.8T patent/DK3229828T5/da active
- 2015-12-10 CN CN201580075896.2A patent/CN107206058A/zh active Pending
- 2015-12-10 JP JP2017531157A patent/JP6970615B2/ja active Active
- 2015-12-10 NZ NZ733670A patent/NZ733670A/en unknown
- 2015-12-10 ES ES15808177T patent/ES2949095T3/es active Active
- 2015-12-10 TW TW104141448A patent/TWI758239B/zh active
- 2015-12-10 TN TN2017000235A patent/TN2017000235A1/en unknown
- 2015-12-10 RS RS20230477A patent/RS64300B1/sr unknown
- 2015-12-10 AU AU2015359376A patent/AU2015359376B2/en active Active
-
2017
- 2017-06-09 CL CL2017001483A patent/CL2017001483A1/es unknown
- 2017-06-09 PH PH12017501084A patent/PH12017501084A1/en unknown
- 2017-06-11 IL IL252803A patent/IL252803B/en unknown
- 2017-06-12 GT GT201700124A patent/GT201700124A/es unknown
- 2017-07-10 CO CONC2017/0006898A patent/CO2017006898A2/es unknown
- 2017-07-11 EC ECIEPI201744282A patent/ECSP17044282A/es unknown
-
2018
- 2018-08-10 US US15/914,197 patent/US20190060411A1/en not_active Abandoned
-
2019
- 2019-04-17 US US16/387,178 patent/US20190381145A1/en not_active Abandoned
-
2020
- 2020-08-17 US US16/995,466 patent/US20210128692A1/en not_active Abandoned
-
2022
- 2022-04-28 US US17/731,371 patent/US12186374B2/en active Active
-
2024
- 2024-11-08 US US18/940,909 patent/US20250177487A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ733670A (en) | Insulin glargine/lixisenatide fixed ratio formulation | |
| PH12015502755A1 (en) | Insulin glargine / lixisenatide fixed ratio formulation | |
| MX2016016666A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
| MX2016015093A (es) | Derivados de acido boronico y sus usos terapeuticos. | |
| WO2015106269A3 (en) | Rapid action insulin formulations and pharmaceutical delivery systems | |
| IL240949B (en) | Aqueous pharmaceutical formulation for use in the treatment of type 1 or type 2 juvenile diabetes | |
| SG11201908281VA (en) | Phenalene-1-one-containing photosensitizer composition, phenalene-1-one compound and the use thereof | |
| MX389026B (es) | Una composicion farmaceutica y el uso de la misma. | |
| PH12018501709A1 (en) | Naphthridinedione derivatives | |
| MX2017009294A (es) | Tratamiento de pacientes pediatricos con diabetes mellitus de tipo 2 con lixisenatida. | |
| WO2015173427A3 (fr) | Composition a action rapide d'insuline comprenant un compose anionique substitue et un compose polyanionique | |
| EP3265503A4 (en) | Polymeric metformin and its use as a therapeutic agent and as a delivery vehicle | |
| PH12017501979A1 (en) | Pharmaceutical compound | |
| WO2016020408A3 (en) | Compounds for preventing ototoxicity | |
| GB2543709A (en) | Pharmaceutical agent | |
| PL3501507T3 (pl) | Makrogole do aplikacji dośluzówkowej i ich zastosowania terapeutyczne | |
| PH12018500579A1 (en) | Fungal keratitis prophylactic or therapeutic agent | |
| GT201600190A (es) | Compuestos químicos | |
| WO2015181837A3 (en) | Novel compounds as anti-tubercular agents | |
| AR102978A1 (es) | Formulación de relación fija de insulina glargina / lixisenatida | |
| EA201791296A1 (ru) | Состав с постоянным соотношением инсулин гларгин/ликсисенатид | |
| HK1228762A1 (en) | Rapid action insulin formulations and pharmaceutical delivery systems | |
| HK1239554B (en) | Insulin glargine/lixisenatide fixed ratio formulation | |
| HK1239554A1 (en) | Insulin glargine/lixisenatide fixed ratio formulation | |
| IN2014MU01326A (cg-RX-API-DMAC7.html) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 DEC 2023 BY CPA GLOBAL Effective date: 20221027 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 DEC 2024 BY CPA GLOBAL Effective date: 20231026 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 DEC 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20241101 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 DEC 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20251024 |